| You are here: Home: BCU 3|2004: Gary H Lyman, MD, MPH, FRCP: Select publications
Select publications
Armstrong DK, Davidson NE. Dose intensity for breast cancer. Oncology (Huntingt) 2001;15(6):701-8, 712; discussion 712-4;717-8. Abstract
Bonadonna G et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332(14):901-6. Abstract
Budman DR et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90(16):1205-11. Abstract
Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer 2000;36(Suppl 1):11-4. Abstract
Foote M. The importance of planned dose of chemotherapy on time: Do we need to change our clinical practice? Oncologist 1998;3(5):365-8. Abstract
Goldhirsch A et al. Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group. J Clin Oncol 1998;16(4):1358-62. Abstract
Henderson IC et al. Dose-response in the treatment of breast cancer: A critical review. J Clin Oncol 1988;6(9):1501-15. Abstract
Henderson IC et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21(6):976-83. Abstract
Hryniuk W et al. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose-intensity. J Clin Oncol 1998;16(9):3137-47. Abstract
Link BK et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: Current patterns of care. Cancer 2001;92(6):1354-67. Abstract
Lyman GH. A novel approach to maintain planned dose chemotherapy on time: A decision-making tool to improve patient care. Eur J Cancer 2000;36(Suppl 1):15-21. Abstract
Lyman GH et al. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J Clin Oncol 2003;21(24):4524-31. Abstract
Silber JH et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998;16(7):2392-400. Abstract
Wood WC et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330(18):1253-9. Abstract
|
